RXi Aims for First Clinical Trial in 2012 | GenomeWeb

RXi Pharmaceuticals this week said that it has begun formal development of its lead dermal anti-scarring candidate RXI-109, and expects to submit an investigational new drug application for the compound in the second half of the year, with human testing beginning in 2012.

The company also said that it plans to test the safety and efficacy of the drug in the first clinical trial of RXI-109. Specifically, RXi said that it will evaluate the agent's ability to reduce dermal scarring in planned surgeries.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.